| NCT ID | NCT02039752 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Seung-Jung Park |
| Condition | Coronary Artery Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 25,000 participants |
| Start Date | 2014-03 |
| Primary Completion | 2030-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25,000 participants in total. It began in 2014-03 with a primary completion date of 2030-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate long-term prognoses of patients with multivessel coronary disease treated medically or surgically or percutaneously in real world practice.
Eligibility Criteria
Inclusion Criteria: * Patients with multivessel disease from 1995 in Asan Medical Center * Age 19 and more Exclusion Criteria: * For prospective cohort, not agreeing to participate with written informed consent form
Frequently Asked Questions
Who can join the NCT02039752 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02039752 currently recruiting?
Yes, NCT02039752 is actively recruiting participants. Visit ClinicalTrials.gov or contact Seung-Jung Park to inquire about joining.
Where is the NCT02039752 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT02039752 clinical trial?
NCT02039752 is sponsored by Seung-Jung Park. The trial plans to enroll 25,000 participants.